The new generation of
Non-Invasive Prenatal Test.

From Labco one of Europes leaders in Diagnostic testing.

  • NeoBona - Header 1

Current situation

A conventional first-trimester screening only provides a statistical risk index.

New technology

neoBona detects possible chromosomal abnormalities in the future baby using one of the most advanced technology with no risk for the fetus.


LABCO is a pioneer in new advances that make it possible to offer a non-invasive prenatal test on maternal blood giving accurate results in one week.

Around 1% of fetuses have some type of chromosomal abnormality. neoBona  is the new generation non-invasive prenatal test backed by the experience of LABCO, one of the European leaders in diagnostic testing.

What is neoBona?

The new generation of Non-Invasive Prenatal test


Thanks to the cutting edge technology.


Results available in 5 working days.


Sensitivity higher than 99.9% for Downs and Patau's Syndromes.



With no risk for the mother and the fetus.


A single blood sample from the mother.


Supported by LABCO, one of Europes pioneers and leaders in Prenatal Diagnosis.

NeoBona - anomalias

Detects abnormalities

Detects the most frequent chromosomal abnormalities that occur during pregnancy by studying the cell-free fetal DNA present in the maternal blood.

NeoBona - tecnologa-avanzada

Incorporates advanced technology

neoBona incorporates the paired-end sequencing technology from Illumina, one of the world leaders in DNA sequencing, that provides a greater precision and sensibility. This technology is offered exclusively by LABCO.

NeoBona - precisin

Accuracy of the analysis

The test analyzes the amount of cell-free fetal DNA present in the maternal blood (fetal fraction) as well as the cell-free DNA fragments size, which has been demonstrated to increase the precision of the analysis.

NeoBona - gestacin-en

I am pregnant, is neoBona suitable for me?

  • Is available from the 10th week of gestation.
  • Can be performed in cases of assisted reproduction, including IVF through egg donation.
  • Is suitable for twins.
  • neoBona is a genetic screening test and as such, must be requested  by a clinician.

Why choose neoBona?


neoBona offers confidence for the early detection of chromosomal abnormalities in the fetus, with no risk to the mother or the future baby.


neoBona is the only prenatal test available that has the support of LABCO and their extensive team of over 600 medical professionals and genetics experts, at disposal of your physician to bring you a comprehensive medical attention.


LABCO is the only lab capable to offer you the largest draw center net in Europe.


Developed with Illumina, a world leader in DNA sequencing, integrating technology and knowledge to offer an innovative non-invasive prenatal test.


Unlike other prenatal tests, neoBona measures the presence of cell-free fetal DNA in the blood sample from the mother, improving the reliability of the result.

NeoBona - feto en


It is the first test that combines the depth of sequencing, the percentage of fetal DNA and the measurement of the fragments size in a new algorithm named TSCORE which allows reliable results even at a low fetal fraction.


The combined screening consists of a blood analysis and an ultrasound and only provides a statistical risk index. neoBona provides greater performance due to it is based on the study of the cell-free fetal DNA.


The sensitivity of conventional screening is 90%, this means that out of every 100 fetuses with Down’s Syndrome, traditional screening would not detect 10 cases. The sensitivity of neoBona is higher than 99.9%, meaning that it detects practically all cases of Down’s Syndrome.


The specificity of conventional screening is 95%, which implies a false positive rate of 5%, this means that out of every 100 healthy fetuses, 5 are classified as positive and maybe subjected to invasive procedures that involve certain risk for the mother and fetus. The high specificity of neoBona makes it possible to reduce the number of false positives to practically zero (<0.1%), thus preventing a significant number of unnecessary invasive procedures.

What types of chromosomal abnormalities does it detect?

1. Most frequent trisomies

A trisomy is caused by the presence of three copies of a chromosome instead of the regular two. neoBona detects the following trisomies:

  • Trisomy 21, or Downs Syndrome, is the most common trisomy.
  • Trisomy 18, or Edwards Syndrome, has a high incidence of miscarriage. This chromosomal abnormality has a high mortality rate.
  • Trisomy 13, or Pataus Syndrome, is related to a high incidence of miscarriage. This chromosomal abnormality has a high mortality rate.

2. Alterations in sex chromosomes

neoBona detects alterations in the number of sex chromosomes, including:

  • Turner Syndrome (45, X), the absence of an X chromosome in girls.
  • Klinefelter Syndrome (47, XXY), the presence of an extra copy of the X chromosome in boys.

3. Microdeletions and other trisomies

There is an option that includes the analysis of small changes in the chromosomes, known as microdeletions, as well as the trisomies 16 and 9.

If the result of neoBona is consistent with an alteration on chromosomes 21, 18, 13, X and Y, LABCO offers a free confirmation of the result by QF-PCR. To perform the test it is necessary to provide an amniotic fluid or chorionic villus sample.

Types of neoBona tests

There are three types of tests available, you can evaluate with your physician which one is the most appropriate for you.


Trisomies 21, 18, and 13 + Fetal sex (optional)
Paired-end NGS technology
Fetal fraction 

neoBona Advanced

Trisomies 21, 18, and 13 + Fetal sex + Sex chromosomes (X and Y)
Paired-end NGS technology
Fetal fraction 

neoBona Advanced +

Trisomies 21, 18, and 13 + Fetal sex + Sex chromosomes (X and Y) + Trisomies 16 and 9 + Microdeletions panel
NGS technology
Without fetal fraction

* Option available for twins. In this case if "Fetal sex" option is selected, the presence of Y chromosome is determined.

LABCO Quality Diagnostics

One of Europe's leaders in Diagnostics service

More than 15 years innovating in prenatal diagnosis.

Operates in 35 countries in Europe, Latin America, and Africa.

More than 400 million tests a year.

The company has a network of over 450 laboratories.

Over 600 medical professionals and genetics experts.

Detection rate

T21> 99,9%
T18> 97%
T13> 99,9%


Request more information

* Required fields.